Journal
PHARMACOLOGY & THERAPEUTICS
Volume 220, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2020.107717
Keywords
Necroptosis; Cell programmed necrosis; Cell death; RIPK1; RIPK3; MLKL; Neurodegenerative diseases; Cardiovascular disorders; Cancer
Categories
Funding
- Michigan Ovarian Cancer Alliance (MIOCA)
- Marsha Rivkin Ovarian Center pilot award
- Elsa U. Pardee foundation
- Foundation for Women's Cancer
- Liz Tilberis early career OCRA award
Ask authors/readers for more resources
Programmed cell death (PCD) has been a major research interest in the past three decades. Initially, apoptosis was considered the only mechanistic pathway for PCD, but now other important pathways such as necroptosis have been discovered, which are crucial for understanding the cellular processes behind different pathological conditions. Additionally, research on triggering necroptosis in cancer cells to induce cell death and overcome chemoresistance is being discussed.
Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance. (c) 2020 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available